462 related articles for article (PubMed ID: 27834353)
1. Combinatorial immunotherapy for melanoma.
George DD; Armenio VA; Katz SC
Cancer Gene Ther; 2017 Mar; 24(3):141-147. PubMed ID: 27834353
[TBL] [Abstract][Full Text] [Related]
2. The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors.
Andtbacka RH
Clin Adv Hematol Oncol; 2016 Aug; 14(8):576-9. PubMed ID: 27487099
[No Abstract] [Full Text] [Related]
3. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
5. Novel Targets for the Treatment of Melanoma.
Ambrosi L; Khan S; Carvajal RD; Yang J
Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
[TBL] [Abstract][Full Text] [Related]
6. Combination Immunotherapy Development in Melanoma.
Eggermont AMM; Crittenden M; Wargo J
Am Soc Clin Oncol Educ Book; 2018 May; 38():197-207. PubMed ID: 30231333
[TBL] [Abstract][Full Text] [Related]
7. Injectable Therapies for Regional Melanoma.
Farrow NE; Leddy M; Landa K; Beasley GM
Surg Oncol Clin N Am; 2020 Jul; 29(3):433-444. PubMed ID: 32482318
[TBL] [Abstract][Full Text] [Related]
8. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
9. Sequencing of New and Old Therapies for Metastatic Melanoma.
Ratterman M; Hallmeyer S; Richards J
Curr Treat Options Oncol; 2016 Oct; 17(10):52. PubMed ID: 27515170
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
11. Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
Br J Dermatol; 2018 Jul; 179(1):213-215. PubMed ID: 29405254
[No Abstract] [Full Text] [Related]
12. Oncolytic virus therapy in advanced melanoma.
Gourd E
Lancet Oncol; 2017 Nov; 18(11):e649. PubMed ID: 29033197
[No Abstract] [Full Text] [Related]
13. Combinatorial approach to treatment of melanoma.
Ashworth MT; Daud AI
Hematol Oncol Clin North Am; 2014 Jun; 28(3):601-12. PubMed ID: 24880950
[TBL] [Abstract][Full Text] [Related]
14. Surgical Considerations and Systemic Therapy of Melanoma.
Gamboa AC; Lowe M; Yushak ML; Delman KA
Surg Clin North Am; 2020 Feb; 100(1):141-159. PubMed ID: 31753109
[TBL] [Abstract][Full Text] [Related]
15. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
McKean MA; Amaria RN
Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
[TBL] [Abstract][Full Text] [Related]
16. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials.
Ascierto PA; Long GV
Lancet Oncol; 2016 Aug; 17(8):1037-1039. PubMed ID: 27324281
[No Abstract] [Full Text] [Related]
17. Updates in Melanoma.
Tracey EH; Vij A
Dermatol Clin; 2019 Jan; 37(1):73-82. PubMed ID: 30466690
[TBL] [Abstract][Full Text] [Related]
18. An Overview of the Changing Landscape of Treatment forĀ Advanced Melanoma.
Lee CS; Thomas CM; Ng KE
Pharmacotherapy; 2017 Mar; 37(3):319-333. PubMed ID: 28052356
[TBL] [Abstract][Full Text] [Related]
19. The importance for immunoregulation for long-term cancer control.
Fusi A; Dalgleish A
Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
[TBL] [Abstract][Full Text] [Related]
20. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]